PIM kinases (especially PIM2) have already been proposed as therapeutic targets in DLBCL, especially in ABC-DLBCL cases with aggressive behavior after R-CHOP treatment [48,49]. Here, PIM2 is linked to diffuse large B-cell lymphoma.